Description
The
125I-hLH IRMA system provides direct quantitative
determination of human Luteinizing Hormone (hLH) in human serum. hLH can
be assayed in the range of 0-150 mIU/ml using 100 µl serum samples. Each
kit contains materials sufficient for 100 assay tubes permitting the
construction of one standard curve and the assay of 42 unknowns in
duplicate.
Introduction
The human luteinizing hormone (lutropin or LH)
is a glycoprotein with a molecular weight of 30000, secreted by the
adenohypophysis. Like other glycoprotein hormones (FSH, TSH and HCG),
hLH contains two different subunits, an a-
and a ß-chain, linked by noncovalent bounds. The primary structures of
the a subunits of hLH and of those mentioned
are virtually identical, whilst their ß subunits are different. The ß
subunits are responsible for the immunological and biological
specificity of these hormones.
Human luteinizing hormone synthesis and
release is stimulated by the hypothalamic gonadotropin releasing hormone
(GnRH), whereas the ovarian steroids secreted from the corpus luteum
control further secretions of hLH by negative feedback.
The measurement of luteinizing hormone
concentrations is an important part of the investigation of disorders of
the hypothalamic-pituitary-gonadal axis. It is recommended to measure
both hLH and hFSH to discriminate between hypothalamic and pituitary
dysfunction.
Principle of method
The technology uses two high affinity
monoclonal antibodies in an immunoradiometric assay (IRMA) system. It
offers an increased level of sensitivity and specificity compared with
conventional RIA methods.
The 125I labelled signal-antibody
binds to an epitope of the hLH molecule different from that recognised
by the unlabelled capture-antibody. The two antibodies react
simultaneously with the hLH molecule forming a “sandwich”.
Standards and samples are incubated with a
mixture of the antibodies at room temperature. At the end of a one hour
incubation period (no need of a shaker), magnetic immunosorbent (MIS) is
added in excess. MIS particles selectively bind the hLH – signal
antibody – capture antibody complex and settle out in a magnetic field.
A wash step is critical to reducing non-specific binding to a minimum
for increased low end precision. By measuring the radioactivity of the
magnetic immunosorbent pellet in a gamma counter the luteinizing hormone
concentration can be determined.
Contents of the kit
|
1 bottle |
TRACER, Ready to use.
21 ml, containing about 740 kBq 125I-anti-hLH and
capture anti-hLH in buffer
with red dye and 0.1% NaN3. |
|
6 vials |
STANDARDS, Ready to use.
1.0 ml per vial, containing 0, 0.4, 2.0, 10, 40, 150 mIU/ml (WHO
2nd IS 80/552 Int.Std.) in serum with 0.1% NaN3 |
|
1 vial |
CONTROL SERUM.
Lyophilized human serum with 0.1% NaN3
The concentration of the control serum is specified in the
quality certificate enclosed. See Preparation of reagents |
|
1 bottle |
MAGNETIC IMMUNOSORBENT (MIS).
Ready to use.
55 ml, containing paramagnetic particles in buffer with 0.1% NaN3. |
|
1 vial |
WASH BUFFER CONCENTRATE.
20 ml, containing 0.1% NaN3. See Preparation of
reagents |
|
1 pc |
Quality certificate |
|
1 pc |
Pack leaflet |
Materials, and equipment required
Test
tube rack
Precision pipettes with disposable tip (100, 200 and 1000 µl)
Distilled water
Vortex mixer
Shaker
Plastic foil
Gamma counter
Absorbent tissue
Recommended
tools and equipment
Repeating pipettes (e.g. Eppendorf)
Dispenser with 300 ml reservoir (instead of the 2 ml pipette)
Specimen collection and storage
Serum
samples can be prepared according to common procedures used routinely in
clinical laboratory practice. Samples can be stored at 2-8 °C if the
assay is carried out within 24 hours, otherwise aliquots should be
prepared and stored deep frozen (-20 °C). Frozen samples should be
thawed and thoroughly mixed before assaying. Repeated freezing and
thawing should be avoided. Do not use lipemic, hemolyzed or turbid
specimens. Samples with a hLH concentration higher than that of the most
concentrated standard should be diluted and reassayed.
Preparation of reagents, storage
Add the
wash buffer concentrate (20 ml) to 200 ml distilled water to obtain 220
ml wash solution. Upon dilution store at 2-8 °C until expiry date.
Add
1000 µl distilled water to the lyophilized control serum. Mix gently
with shaking or vortexing (foaming should be avoided).
Ensure
that complete dissolution is achieved, and allow the solution to
equilibrate at room temperature for at least 20 minutes. Store at -20 °C
until expiry date.
Store
the rest of reagents between 2-8 °C after opening. At this temperature
each reagent is stable until expiry date. The actual expiry date is
given on the package label and in the quality certificate.
CAUTION! Equilibrate all reagents and serum samples to room temperature.
Mix all reagents and samples thoroughly before use. Avoid excessive
foaming.
Assay procedure
(For a quick
guide, refer to Table 1.)
|
1 |
Equilibrate reagents and samples to room temperature
before use. |
|
2 |
Label tubes in duplicate for total counts (T), each
standard (S1-S6), control serums and samples. |
|
3 |
Homogenize all reagents and samples by gentle mixing to
avoid foaming. |
|
4 |
Pipette 100 µl of standards, controls and samples into
the properly labelled tubes. Use rack to hold the tubes. |
|
5 |
Pipette 200 µl of tracer into each tube. |
|
6 |
Thoroughly vortex mix all tubes except T for 2-5 seconds.
When having an orbital shaker, leave all tubes in the rack
holder, fix the holder onto the plate of the shaker, and shake
it gently for a few seconds. |
|
7 |
Incubate tubes for 1 hours, at room temperature. |
|
8 |
Place T tubes on a separate tube rack. Gently shake and
swirl the bottle containing magnetic immunosorbent until
homogeneity is achieved. Add 500 µl MIS to each tube except T.
When using a single pipette, swirl the bottle of MIS after every
15-20 tubes. With the use of a repeating pipette (e.g.
Eppendorf), there is no need for repeated homogenisation of MIS
reagent. |
|
9 |
Thoroughly vortex mix all tubes, and incubate them for 15
minutes at room temperature. |
|
10 |
Attach the rack on to the magnetic separator base and
ensure that every tube is in contact with the base plate. Let
the MIS particles settle for 5 minutes. Do not remove the rack
from the separator base after the separation of the solid and
liquid phases. Pour off and discard the supernatant. Keeping the
separator inverted, place the tubes on a pad of absorbent tissue
and allow to drain for 2 minutes. |
|
11 |
Return the separator to an upright position and add 1.0
ml of washing solution to each tube. For more comfort and
precision, it is recommended to use either a repeating pipette
(e.g. Eppendorf-pipette) or a dispenser with bottle for the
addition of washing solution. |
|
12 |
Vortex mix each tube thoroughly and repeat Step 10.
Intense vortexing is required when working with a singular
pipette, but repipettors will inject the washing solution
efficiently enough to have the pellett resuspended even without
a subsequent vortexing step. |
|
13 |
Count each tube for at least 60 seconds in a gamma
counter. |
|
14 |
Calculate the concentrations of the samples as described
in Calculation of results. |
Table
1. Assay Protocol, Pipetting Guide (all volumes in microliters)
|
Tubes |
Total |
Standard |
Sample |
Control |
|
Standard |
|
100 |
|
|
|
Sample |
|
|
100 |
|
|
Control |
|
|
|
100 |
|
Tracer |
200 |
200 |
200 |
200 |
|
Vortex & incubate for 1 hour at room temperature |
|
MIS |
|
500 |
500 |
500 |
|
Vortex & incubate for 15 minutes at room temperature |
|
Separate for 5 minutes |
|
Decant the fluid & blot on filter paper |
|
Wash
Buffer |
|
1000 |
1000 |
1000 |
|
Separate for 5 minutes |
|
Decant the fluid & blot on filter paper |
|
Count radioactivity (60 sec/tube) |
|
Calculate the results |
Table 2.
Typical Assay Data
| |
cpm
1 |
cpm
2 |
cpm
mean |
B / T % |
|
Total |
247100 |
246959 |
247030 |
- |
|
S1 |
295 |
222 |
259 |
0.03 |
|
S2 |
730 |
721 |
492 |
0.23 |
|
S3 |
2918 |
2815 |
2867 |
0.95 |
|
S4 |
12036 |
12280 |
12158 |
4.6 |
|
S5 |
45812 |
45515 |
45664 |
17.6 |
|
S6 |
128680 |
129361 |
129021 |
57.1 |
|
C |
15438 |
15647 |
15543 |
3.7 |

Figure 1
A typical standard curve
(Do not use to calculate unknown samples)
Calculation of results
The
calculation is illustrated using representative data. The assay data
collected should be similar to those shown in Table 2.
Calculate the
average CPM for each pair of assay tubes. Calculate the normalized
percent binding for each standard, control and sample respectively by
using the following equation:
| |
S2-6 [C, Mx] (cpm) - S1
(cpm) |
|
|
B / T % = |
——————————— |
x 100 |
| |
T (cpm) |
|
Using
semi-logarithmic graph paper plot B/T (%) for each standard versus the
corresponding concentration of LH.
Determine the
LH concentration of the unknown samples by interpolation from the
standard curve. Do not extrapolate values beyond the standard curve
range.
Out of fitting
programs applied for computerized data processing logit-log, or spline
fittings can be used. Automated data processing systems are also
available.
Characterization of the assay
Assay parameters
|
NSB / T |
< 0.1% |
|
Bmax / B0 |
> 500 |
Sensitivity
A
detection limit of 0.02 mIU/ml has been obtained by assaying 20
replicates of the zero standard. The sensitivity has been determined as
the concentration corresponding to the sum of the mean cpm and its
double standard deviation.
Hook effect
There is no
high dose “hook effect” up to a hLH concentration of 1000 mIU/ml .
Specificity
No cross reactivity with hFSH and hTSH can be detected in normal
physiological concentrations.
2 000 mIU/ml hCG gives an apparent 3.5 mIU/ml increase in hLH
concentration.
Precision
4 patient
samples were assayed in 15 replicates to determine intra-assay
precision. Values obtained are shown below.
|
Sample |
Number
of replicates |
Mean
value
mIU/ml |
SD
mIU/ml |
CV
% |
|
1 |
15 |
2.06 |
0.06 |
2.98 |
|
2 |
15 |
4.37 |
0.07 |
1.59 |
|
3 |
15 |
16.0 |
0.30 |
1.88 |
|
4 |
15 |
35.1 |
0.63 |
1.80 |
Reproducibility
To determine
inter-assay precision 4 patient samples were measured in duplicates in
20 independent assays by 2 operators using different kit batches. Values
obtained are shown below.
|
Sample |
Number
of runs |
Mean
value
mIU/ml |
SD
mIU/ml |
CV
% |
|
1 |
20 |
2.08 |
0.07 |
3.22 |
|
2 |
20 |
4.46 |
0.12 |
2.57 |
|
3 |
20 |
16.3 |
0.52 |
3.20 |
|
4 |
20 |
35.9 |
0.72 |
2.00 |
Recovery
Recovery was defined as the measured increase expressed as percent of
expected increase upon spiking serum samples with known amount of hLH.
The average percent recovery for 9 serum pools spiked with hLH at 3
levels was: 98.6 ± 4.3 (mean ± SD)
Expected
Values
|
male: |
|
1.9 - 9.4 mIU/ml |
|
female: |
ovulatory peak |
25 - 94 mIU/ml |
| |
pre- and postovulatory |
0.7 - 9.0 mIU/ml |
| |
postmenopausal |
13 - 80 mIU/ml |
It is
recommended that each laboratory determine a reference range for its own
patient population.
Procedural notes
Addition of wash buffer. For the addition of wash
buffer the use of a common laboratory dispenser equipped with a 300 ml
glass bottle, and a flexible outlet tubing end is recommended. In lack
of this tool a large-volume syringe attached to a repeating pipette can
be used.
Additional information
Components from various lots or from kits of different manufacturers
should not be mixed or interchanged.
Precautions and warnings
Radioactivity
This product
contains radioactive material. It is the responsibility of the user to
ensure that local regulations or code of practice related to the
handling of radioactive materials are satisfied.
Biohazard
Human blood
products used in the kit have been obtained from healthy human donors.
They were tested individually by using approved methods (EIA, enzyme
immunoassay), and were found to be negative, for the presence of both
Human Immunodeficiency Virus antibody (Anti-HIV-1) and Hepatitis B
surface Antigen (HBsAg).
Care
should always be taken when handling human specimens to be tested with
diagnostic kits. Even if the subject has been tested, no method can
offer complete assurance that Hepatitis B Virus, Human Immunodeficiency
Virus (HIV-1), or other infectious agents are absent. Human blood
samples should therefore be handled as potentially infectious
materials.
Chemical
hazard
Components contain sodium azide as an antimicrobial agent. Dispose of
waste by flushing with copious amount of water to avoid build-up of
explosive metallic azides in copper and lead plumbing. The total azide
present in each pack is 74 mg.
 |
Use by |
 |
In vitro diagnostic medical device |
 |
Control |
 |
Batch code |
 |
Manufacturer |
 |
Standard |
 |
Caution, consult accompanying documents |
 |
Radioactive material |
 |
Magnetic immunosorbent |
 |
Biological risk |
 |
Temperature limitation
Store between 2-8 °C |
 |
Tracer |
 |
Consult instructions for use |
 |
Catalogue number |
 |
Wash buffer |
|